Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...
Kesimpta is a medication used to treat relapsing forms of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Kesimpta comes as a solution inside single-dose prefilled injection pens or ...
–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...
Please provide your email address to receive an email when new articles are posted on . Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At ...
Asianet Newsable on MSN
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug
The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of ...
The chronic progressive multiple sclerosis market size is anticipated to grow during the forecast period (2025–2034). According to DelveInsight's ...
Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...
MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback